Introduction

Functional heartburn is a functional esophageal disorder defined by the Rome IV classification as burning retrosternal discomfort or pain that cannot be attributed to gastroesophageal reflux disease (GERD), eosinophilic esophagitis (EoE), or a major esophageal motor disorder. It is designated as category A2 within the Rome IV framework for esophageal disorders and represents a diagnosis of exclusion that can only be reached after a systematic and thorough diagnostic workup.

Heartburn is among the most common symptoms encountered in both primary care and gastroenterology practice. While the majority of patients with heartburn have GERD (either erosive esophagitis or non-erosive reflux disease), a clinically significant subset continues to experience burning retrosternal symptoms despite optimal acid suppression, with objectively normal acid exposure on ambulatory reflux monitoring and no evidence of reflux-symptom correlation. These patients pose a considerable diagnostic and therapeutic challenge, and functional heartburn provides a structured diagnostic label that facilitates appropriate management and helps avoid futile escalation of acid-suppressive therapy.

The Rome IV criteria for functional heartburn, published in 2016, refined and narrowed the definition compared to Rome III, most notably by distinguishing functional heartburn from the newly introduced entity of reflux hypersensitivity. This distinction carries direct clinical implications, as the two conditions have different pathophysiological underpinnings and may respond to different therapeutic strategies.

Classification Within the Rome IV Esophageal Disorders

The Rome IV classification system organizes functional esophageal disorders into a hierarchical framework. Functional heartburn occupies a specific position within this system:

Code	Disorder
A1	Functional Chest Pain
A2	Functional Heartburn
A3	Reflux Hypersensitivity
A4	Globus
A5	Functional Dysphagia

The distinction between A2 (functional heartburn) and A3 (reflux hypersensitivity) is one of the most clinically important refinements introduced by Rome IV. Both conditions present with heartburn symptoms in the absence of erosive esophagitis and with normal esophageal acid exposure on ambulatory pH monitoring. The differentiating factor is whether there is a demonstrable temporal correlation between reflux episodes and symptom perception. In reflux hypersensitivity, such a correlation exists (positive symptom association probability or symptom index), whereas in functional heartburn it does not.

The Rome IV Diagnostic Criteria for Functional Heartburn

The diagnosis of functional heartburn under Rome IV requires that all four of the following diagnostic criteria be satisfied:

1. Burning retrosternal discomfort or pain: The patient reports a burning sensation located behind the sternum as the primary symptom.
2. No symptom relief despite optimal antisecretory therapy: Symptoms persist despite an adequate trial of proton pump inhibitor (PPI) therapy at standard or double dose for at least 8 weeks.
3. Absence of evidence that gastroesophageal reflux or eosinophilic esophagitis is the cause of the symptom: Normal endoscopy (no erosive esophagitis, no histological evidence of EoE), normal acid exposure on ambulatory reflux monitoring, and no positive reflux-symptom correlation.
4. Absence of major esophageal motor disorders: High-resolution manometry (HRM) excludes achalasia/esophagogastric junction (EGJ) outflow obstruction, diffuse esophageal spasm, jackhammer esophagus, and absent peristalsis.

Temporal Requirements

In addition to the four diagnostic criteria above, the following temporal conditions must all be met:

• Symptoms present for the last 3 months: The criteria must be fulfilled for at least the most recent 3 consecutive months.
• Symptom onset at least 6 months before diagnosis: The initial onset of burning retrosternal symptoms must have occurred at least 6 months prior to the current evaluation.
• Symptom frequency of at least twice per week: The burning retrosternal discomfort must occur on average at least 2 days per week.

Functional heartburn is unique among the Rome IV esophageal disorders in requiring both a comprehensive negative diagnostic workup and failure of empiric acid-suppressive therapy before the diagnosis can be applied. It cannot be made on clinical grounds alone.

Detailed Examination of Each Diagnostic Criterion

Criterion 1: Burning Retrosternal Discomfort or Pain

The cardinal symptom of functional heartburn is a burning sensation localized behind the sternum. This is the same symptom quality described by patients with GERD, which is precisely why a thorough workup is required to distinguish the two conditions. The burning character is important: patients who describe their primary symptom as pressure, tightness, or non-burning chest pain may instead meet criteria for functional chest pain (Rome IV A1) rather than functional heartburn.

Clinicians should use open-ended questioning to characterize the symptom accurately. Asking the patient to describe the sensation in their own words, to localize it by pointing to the area of maximal discomfort, and to describe any radiation pattern helps determine whether the presentation is truly heartburn or another form of chest discomfort. The retrosternal location is essential; epigastric burning without retrosternal extension may point toward functional dyspepsia rather than functional heartburn.

Criterion 2: No Symptom Relief Despite Optimal Antisecretory Therapy

This criterion requires that the patient has undergone an adequate trial of PPI therapy without meaningful symptomatic improvement. The Rome IV committee defines an adequate PPI trial as treatment with a standard or double-dose PPI administered for at least 8 weeks, with the medication taken 30 to 60 minutes before meals to ensure optimal bioavailability.

Before concluding that a patient is a true PPI non-responder, clinicians should verify the following:

• Correct dosing: The PPI should be taken at standard dose (e.g., omeprazole 20 mg, lansoprazole 30 mg, esomeprazole 20-40 mg, rabeprazole 20 mg, or pantoprazole 40 mg) once or twice daily.
• Correct timing: PPIs should be taken 30 to 60 minutes before the first meal of the day (and before dinner if on twice-daily dosing) to coincide with maximal parietal cell activation.
• Adequate duration: At least 8 weeks of consistent therapy. Many patients are labeled as PPI failures after inadequate trial durations.
• Adherence: Medication non-adherence is one of the most common reasons for apparent PPI failure. Studies have shown that up to 50 percent of patients prescribed PPIs do not take them as directed.

If there is any doubt about adherence or dosing adequacy, the PPI trial should be repeated under supervised conditions before applying the functional heartburn label. Some experts advocate for objective confirmation of adequate acid suppression using ambulatory pH monitoring performed while the patient is on PPI therapy (on-PPI testing), which simultaneously verifies adherence and documents the degree of acid suppression achieved.

Criterion 3: Absence of Evidence That GERD or EoE Is the Cause

This criterion mandates objective exclusion of both gastroesophageal reflux disease and eosinophilic esophagitis as the cause of the patient's symptoms. The required workup includes:

Upper Endoscopy (Esophagogastroduodenoscopy)

Endoscopy should be performed to evaluate for erosive esophagitis (Los Angeles classification grades A through D), Barrett's esophagus, peptic stricture, and macroscopic findings suggestive of EoE (rings, furrows, exudates, strictures, edema). Esophageal biopsies should be obtained from the proximal and distal esophagus to evaluate for EoE histologically (defined as at least 15 eosinophils per high-power field in the absence of other causes of esophageal eosinophilia). A normal endoscopy with negative biopsies satisfies this component of the criterion.

Ambulatory Reflux Monitoring

Ambulatory reflux monitoring is the cornerstone investigation for distinguishing functional heartburn from non-erosive reflux disease (NERD) and reflux hypersensitivity. Two primary modalities are available:

• Catheter-based pH monitoring (24-hour): A thin catheter with a pH sensor is placed transnasally and positioned 5 cm above the lower esophageal sphincter. It continuously records esophageal pH for 24 hours. The primary metric is the percentage of total time that esophageal pH is below 4 (acid exposure time, or AET). An AET greater than 6 percent is considered definitively abnormal, while an AET below 4 percent is considered definitively normal.
• Wireless pH capsule (Bravo) monitoring (48-96 hours): A capsule is endoscopically attached to the esophageal mucosa and transmits pH data wirelessly. The extended recording period improves diagnostic yield by capturing day-to-day variability in acid exposure.
• Combined pH-impedance monitoring: This technique detects both acid and non-acid (weakly acidic, weakly alkaline) reflux episodes by measuring changes in intraluminal impedance along with pH. It provides the most comprehensive assessment of reflux burden and is particularly valuable in patients tested on PPI therapy, where non-acid reflux episodes may predominate.

For functional heartburn diagnosis, ambulatory reflux monitoring must demonstrate normal acid exposure and the absence of a positive reflux-symptom correlation. The two most commonly used symptom correlation metrics are the Symptom Index (SI) and the Symptom Association Probability (SAP). A negative SI (below 50 percent) and a negative SAP (below 95 percent) indicate that the patient's heartburn episodes are not temporally linked to reflux events.

Distinguishing Functional Heartburn from Reflux Hypersensitivity

When ambulatory reflux monitoring shows normal acid exposure but a positive symptom-reflux correlation (positive SI or SAP), the diagnosis is reflux hypersensitivity (Rome IV A3) rather than functional heartburn. This distinction is critical because reflux hypersensitivity patients may derive some benefit from anti-reflux measures and low-dose acid suppression, whereas functional heartburn patients are unlikely to benefit from any reflux-directed therapy.

Criterion 4: Absence of Major Esophageal Motor Disorders

High-resolution manometry (HRM) is required to exclude major esophageal motor disorders that can produce heartburn-like symptoms. The Chicago Classification (currently version 4.0) defines the following major motor disorders that must be ruled out:

Motor Disorder	Key Manometric Finding
Achalasia (Types I-III)	Impaired EGJ relaxation (elevated integrated relaxation pressure) with absent peristalsis (Type I), panesophageal pressurization (Type II), or spastic contractions (Type III)
EGJ Outflow Obstruction	Elevated integrated relaxation pressure with preserved peristalsis
Diffuse Esophageal Spasm	Premature contractions (reduced distal latency <4.5 seconds) in ≥20% of swallows
Jackhammer Esophagus	Hypercontractile swallows (distal contractile integral >8,000 mmHg·s·cm) in ≥20% of swallows
Absent Peristalsis	100% failed peristalsis with normal EGJ relaxation

Esophageal motor disorders, particularly achalasia (especially Type III) and diffuse esophageal spasm, can produce retrosternal burning or pain that is clinically indistinguishable from heartburn. These conditions require specific treatment (such as pneumatic dilation, surgical myotomy, or peroral endoscopic myotomy for achalasia), making their exclusion essential before a diagnosis of functional heartburn is assigned.

Minor motility findings on HRM, such as ineffective esophageal motility (IEM) or fragmented peristalsis, do not exclude a diagnosis of functional heartburn. These minor abnormalities are common in the general population and are not considered causative of heartburn symptoms.

The Diagnostic Algorithm: A Stepwise Approach

The diagnosis of functional heartburn follows a structured, stepwise algorithm that progressively narrows the differential diagnosis:

1. Step 1: Empiric PPI trial. Initiate standard-dose PPI therapy for 8 weeks. If symptoms resolve, the working diagnosis is GERD (acid-responsive heartburn). If symptoms persist, proceed to Step 2.
2. Step 2: Optimize and escalate PPI therapy. Increase to double-dose PPI for an additional 8 weeks. Verify correct timing (30-60 minutes before meals) and adherence. If symptoms resolve, manage as PPI-responsive GERD. If symptoms persist, proceed to Step 3.
3. Step 3: Upper endoscopy with biopsies. Perform EGD to evaluate for erosive esophagitis, Barrett's esophagus, EoE (with biopsies), and other mucosal pathology. If erosive esophagitis or EoE is identified, treat accordingly. If endoscopy is normal, proceed to Step 4.
4. Step 4: Ambulatory reflux monitoring off PPI. Perform 24 to 96-hour ambulatory pH or pH-impedance monitoring with the patient off PPI therapy for at least 7 days. Assess acid exposure time and symptom-reflux correlation. If AET is abnormal, the diagnosis is NERD. If AET is normal but symptom-reflux correlation is positive, the diagnosis is reflux hypersensitivity (A3). If AET is normal and symptom-reflux correlation is negative, proceed to Step 5.
5. Step 5: High-resolution manometry. Perform HRM to exclude major esophageal motor disorders. If a major motor disorder is identified, treat accordingly. If HRM is normal or shows only minor motility abnormalities, and all temporal criteria are met, the diagnosis of functional heartburn (A2) is established.

Epidemiology

The true prevalence of functional heartburn is difficult to determine because the diagnosis requires a comprehensive negative workup that is not routinely performed in all patients with heartburn. However, available data suggest that functional heartburn accounts for a substantial minority of patients with refractory heartburn symptoms.

Among patients referred to tertiary care centers for PPI-refractory heartburn, studies using Rome III and Rome IV criteria have found that approximately 20 to 40 percent ultimately receive a diagnosis of functional heartburn after completion of the recommended workup. When reflux hypersensitivity (which was grouped with functional heartburn under Rome III) is counted separately under Rome IV definitions, the prevalence of isolated functional heartburn is somewhat lower, estimated at 15 to 25 percent of the PPI-refractory population.

Functional heartburn appears to be more common in women than in men, consistent with the general pattern observed across functional gastrointestinal disorders. It can present at any age but is most commonly diagnosed in adults between 30 and 60 years of age. Patients with functional heartburn have higher rates of anxiety, depression, somatization, and other functional gastrointestinal diagnoses (such as functional dyspepsia and irritable bowel syndrome) compared to patients with GERD.

Pathophysiology

The pathophysiology of functional heartburn is incompletely understood but is believed to involve peripheral and central mechanisms of esophageal hypersensitivity that operate independently of acid exposure and reflux events.

Peripheral Esophageal Hypersensitivity

The esophageal mucosa contains a dense network of sensory nerve fibers, including vagal and spinal afferents that mediate both nociceptive and non-nociceptive signals. In functional heartburn, there is evidence of upregulated expression of pain-related receptors on esophageal sensory neurons, including transient receptor potential vanilloid 1 (TRPV1), acid-sensing ion channels (ASICs), and protease-activated receptors (PARs). These molecular changes lower the threshold for activation of esophageal nociceptors, such that stimuli that would normally be imperceptible (including minor physiological reflux events, esophageal distension, or temperature changes) are perceived as burning pain.

Dilated intercellular spaces (DIS) in the esophageal epithelium, which permit increased paracellular permeability to luminal contents, have been described in both GERD and functional heartburn. In functional heartburn, DIS may allow sub-threshold concentrations of acid, bile, or other irritants to reach and sensitize mucosal nerve endings, even when overall acid exposure is quantitatively normal.

Central Sensitization and Brain-Gut Axis Dysregulation

Central sensitization refers to an amplification of neural signaling within the central nervous system that produces pain hypersensitivity. In functional heartburn, altered processing of esophageal afferent signals has been demonstrated using functional brain imaging. Areas of the brain involved in pain perception, emotional regulation, and visceral sensory processing, including the anterior cingulate cortex, insula, prefrontal cortex, and somatosensory cortex, show abnormal activation patterns in response to esophageal stimulation.

The strong association between functional heartburn and psychological comorbidities (anxiety, depression, catastrophizing, hypervigilance) supports the role of central mechanisms. Psychological distress may lower the threshold for conscious perception of esophageal stimuli through descending facilitation of pain pathways, creating a self-reinforcing cycle of symptom perception and emotional distress.

Autonomic Dysfunction

Alterations in autonomic nervous system function, including reduced vagal tone and sympathetic hyperactivity, have been described in patients with functional esophageal disorders. These autonomic changes may influence esophageal motility, mucosal blood flow, and sensory processing, contributing to symptom generation in functional heartburn.

Mucosal Immune Activation

Emerging evidence suggests that low-grade mucosal inflammation, including increased numbers of mast cells, T lymphocytes, and eosinophils (below the threshold for EoE diagnosis), may be present in the esophageal mucosa of some patients with functional heartburn. These immune cells can release mediators (histamine, tryptase, cytokines) that sensitize nearby sensory nerve endings, providing a potential mechanistic link between mucosal immunity and visceral hypersensitivity.

Differential Diagnosis

Functional heartburn is a diagnosis of exclusion. The following conditions must be systematically considered and ruled out before the diagnosis can be applied.

Gastroesophageal Reflux Disease (GERD)

GERD is the most common cause of heartburn and must be the first condition excluded. GERD encompasses erosive esophagitis (visible mucosal breaks on endoscopy) and non-erosive reflux disease (NERD, defined as normal endoscopy with abnormal acid exposure on ambulatory pH monitoring). Patients with NERD have normal endoscopic findings but demonstrate pathological acid exposure (AET >6%), distinguishing them from functional heartburn patients who have both normal endoscopy and normal acid exposure.

Reflux Hypersensitivity (Rome IV A3)

Reflux hypersensitivity is the condition most closely related to functional heartburn and the most important differential diagnosis. Both conditions present with heartburn, normal endoscopy, and normal acid exposure. The distinguishing feature is the presence of a positive symptom-reflux correlation on ambulatory reflux monitoring in reflux hypersensitivity versus the absence of such a correlation in functional heartburn.

In reflux hypersensitivity, the patient perceives physiological (non-pathological) reflux events as painful, representing heightened esophageal sensitivity to reflux. In functional heartburn, there is no temporal link between reflux events and symptoms, suggesting that the symptom arises from a mechanism other than reflux perception.

Feature	Functional Heartburn (A2)	Reflux Hypersensitivity (A3)	NERD
Endoscopy	Normal	Normal	Normal
Acid Exposure Time	Normal (<4%)	Normal (<4%)	Abnormal (>6%)
Symptom-Reflux Correlation	Negative	Positive	Variable
PPI Response	None/minimal	Partial in some patients	Good in most patients

Eosinophilic Esophagitis (EoE)

EoE is a chronic, immune-mediated esophageal condition characterized by eosinophilic infiltration of the esophageal mucosa. While dysphagia is the most common presenting symptom in adults, heartburn and chest pain can be prominent features, particularly early in the disease course. EoE is excluded by normal esophageal biopsies (fewer than 15 eosinophils per high-power field) obtained during endoscopy. Clinicians should obtain biopsies from at least two esophageal levels (proximal and distal), even if the mucosa appears grossly normal, as EoE can be macroscopically subtle.

Major Esophageal Motor Disorders

Achalasia (especially Type III/spastic achalasia), diffuse esophageal spasm, and jackhammer esophagus can all produce retrosternal burning, chest pain, or a sensation mimicking heartburn. These conditions are excluded by high-resolution manometry. Type III achalasia, in particular, can be diagnostically challenging because it may present primarily with heartburn rather than the classic dysphagia, and its spastic contractions can mimic reflux-related symptoms.

Cardiac Causes

Although not part of the Rome IV criteria per se, it is essential to consider cardiac causes of retrosternal burning or pain before attributing symptoms to a functional esophageal disorder. Coronary artery disease, particularly with atypical presentations, should be excluded through appropriate cardiovascular evaluation in patients with relevant risk factors (age, hypertension, diabetes, hyperlipidemia, smoking, family history).

Other Esophageal and Non-Esophageal Conditions

• Pill esophagitis: Mucosal injury caused by medications (bisphosphonates, doxycycline, NSAIDs, potassium chloride) lodging in the esophagus.
• Infectious esophagitis: Candida, herpes simplex, or cytomegalovirus esophagitis, particularly in immunocompromised patients.
• Rumination syndrome: Effortless, repetitive regurgitation of recently ingested food that can be accompanied by burning.
• Esophageal hypersensitivity to thermal stimuli: Some patients report heartburn triggered specifically by hot or cold foods/beverages, suggesting a temperature-mediated sensory mechanism.

The Role of Impedance Metrics in Diagnosis

Recent advances in ambulatory reflux monitoring have introduced novel impedance-based metrics that may further refine the diagnosis of functional heartburn. Two metrics of particular interest are:

Mean Nocturnal Baseline Impedance (MNBI)

MNBI is a measure of esophageal mucosal integrity assessed during sleep, when swallowing is minimal and reflux events are infrequent. Low MNBI values (<2,292 ohms) indicate impaired mucosal integrity and correlate with pathological reflux, even in patients with borderline acid exposure times. Patients with functional heartburn typically have normal MNBI values, while patients with NERD and reflux hypersensitivity more often have reduced MNBI. This metric can serve as an adjunctive tool to increase diagnostic confidence when AET values fall in the indeterminate range (4-6%).

Post-Reflux Swallow-Induced Peristaltic Wave (PSPW) Index

The PSPW index measures the proportion of reflux events followed within 30 seconds by a peristaltic swallow, reflecting the efficiency of chemical clearance of refluxate from the esophageal mucosa. A low PSPW index (<61%) suggests impaired reflux clearance mechanisms and is more commonly found in GERD and NERD than in functional heartburn. A normal PSPW index supports a functional heartburn diagnosis.

Psychological Comorbidities and Their Clinical Significance

Functional heartburn is strongly associated with psychological comorbidities. Studies have consistently shown higher prevalence rates of generalized anxiety disorder, panic disorder, major depressive disorder, and somatoform disorders in patients with functional heartburn compared to patients with GERD or healthy controls. Several specific psychological constructs are particularly relevant:

• Esophageal hypervigilance: An excessive attentional focus on esophageal sensations, leading to amplified perception of normal physiological events. This can be measured using the Esophageal Hypervigilance and Anxiety Scale (EHAS).
• Symptom catastrophizing: A tendency to magnify the threat value of esophageal symptoms, feel helpless about them, and ruminate about them excessively. Catastrophizing is associated with increased symptom severity and healthcare utilization.
• Anxiety sensitivity: A heightened fear of anxiety-related sensations, which can lead to misinterpretation of normal bodily sensations as threatening.
• Stress reactivity: Acute and chronic psychological stress have been shown to increase esophageal sensitivity to acid and mechanical stimulation, providing a direct physiological mechanism linking stress to symptom exacerbation.

The bidirectional relationship between psychological distress and esophageal symptoms is mediated through the brain-gut axis. Psychological interventions that target these mechanisms, including cognitive behavioral therapy and esophageal-directed hypnotherapy, have shown efficacy in functional heartburn and should be considered integral components of the management plan.

Management of Functional Heartburn

Management of functional heartburn fundamentally differs from GERD management. The cornerstone of treatment shifts from acid suppression to neuromodulation and psychological intervention. A structured, multimodal approach yields the best outcomes.

Step 1: Discontinue Unnecessary Acid Suppression

Once the diagnosis of functional heartburn is established, ongoing PPI therapy should be critically re-evaluated. By definition, the patient has failed to respond to optimal antisecretory therapy, and continued PPI use provides no symptomatic benefit while exposing the patient to potential long-term risks (Clostridioides difficile infection, hypomagnesemia, chronic kidney disease, and osteoporotic fractures, among others). PPIs should be tapered gradually rather than discontinued abruptly, as rebound acid hypersecretion following PPI withdrawal can temporarily worsen symptoms and undermine patient confidence in the new diagnosis.

Step 2: Patient Education and Reassurance

A clear explanation of the diagnosis is therapeutic in itself. Patients with functional heartburn have often undergone extensive testing and multiple failed medication trials, leading to frustration, anxiety, and concern about a missed serious diagnosis. Clinicians should explain that functional heartburn is a well-recognized medical condition caused by heightened sensitivity of the esophageal nerves rather than by acid damage, that it is not dangerous, and that effective treatments exist that target the underlying nerve sensitivity rather than acid production.

Using the term "sensitive esophagus" or "esophageal hypersensitivity" rather than "functional" or "it's in your head" can help patients understand and accept the diagnosis. Visual analogies, such as comparing the condition to a volume knob on a radio that has been turned up too high, making normal signals feel painful, can be effective educational tools.

Step 3: Neuromodulator Therapy

Neuromodulators are the pharmacological cornerstone of functional heartburn treatment. These medications act on central and peripheral pain processing pathways to reduce esophageal sensory perception.

Drug Class	Examples	Typical Dosing	Key Considerations
Tricyclic Antidepressants (TCAs)	Amitriptyline, nortriptyline, imipramine, desipramine	10-50 mg at bedtime, titrated gradually	Best evidence for visceral pain reduction; start low, go slow; anticholinergic side effects (dry mouth, constipation, drowsiness) may limit use
SSRIs	Fluoxetine, sertraline, citalopram, escitalopram	Standard antidepressant doses	Particularly useful when comorbid anxiety or depression is present; less robust evidence for visceral pain than TCAs
SNRIs	Venlafaxine, duloxetine	Standard doses	Dual mechanism may offer advantages for pain; duloxetine has the strongest evidence for chronic pain conditions
Trazodone	Trazodone	100-150 mg at bedtime	Serotonin modulator; some evidence in functional esophageal disorders; sedation can be beneficial if sleep disturbance is present

TCAs, particularly amitriptyline and imipramine at low doses (10-25 mg at bedtime, titrated upward as tolerated), have the most evidence supporting their use in functional esophageal disorders. These agents reduce visceral pain through modulation of descending pain inhibitory pathways and peripheral nerve sensitization. It is important to communicate to patients that the medication is being prescribed for its pain-modulating properties at sub-antidepressant doses, not as a treatment for depression, as this distinction improves adherence and reduces stigma.

Step 4: Psychological and Behavioral Therapies

Psychological interventions have demonstrated significant efficacy in functional esophageal disorders and are increasingly recognized as first-line treatments rather than last-resort options.

• Cognitive Behavioral Therapy (CBT): CBT helps patients identify and modify maladaptive thought patterns (catastrophizing, hypervigilance) and behaviors (avoidance, excessive healthcare seeking) related to their esophageal symptoms. Esophageal-specific CBT protocols have shown durable symptom improvement in functional heartburn.
• Esophageal-Directed Hypnotherapy: Gut-directed hypnotherapy, adapted for esophageal symptoms, uses guided relaxation and therapeutic suggestion to reduce esophageal sensitivity and symptom perception. Randomized controlled trials have demonstrated significant and sustained symptom improvement with this approach.
• Mindfulness-Based Stress Reduction (MBSR): MBSR teaches patients to observe bodily sensations non-judgmentally, reducing the emotional reactivity that amplifies symptom perception.
• Relaxation techniques: Diaphragmatic breathing, progressive muscle relaxation, and biofeedback can reduce sympathetic nervous system activation and lower esophageal sensory thresholds.

Step 5: Complementary and Adjunctive Approaches

• Dietary modification: While no specific diet is evidence-based for functional heartburn, some patients identify individual food triggers (spicy foods, acidic foods, caffeine, alcohol, carbonated beverages) through elimination and reintroduction. A food-symptom diary can help identify patterns.
• Lifestyle modifications: Regular physical activity, adequate sleep, stress management, and avoidance of eating within 3 hours of bedtime may provide incremental benefit.
• Alginate-based formulations: While primarily studied in GERD, alginate preparations (which form a protective raft over the gastric contents) may provide symptomatic relief in some functional heartburn patients through a mucosal protective mechanism independent of acid suppression.

Rome III vs. Rome IV: How the Definition of Functional Heartburn Changed

The Rome IV criteria introduced several important changes compared to the Rome III definition of functional heartburn. Understanding these differences is essential for interpreting older literature and for clinical settings that may still reference Rome III.

Feature	Rome III (2006)	Rome IV (2016)
Definition scope	Included all patients with heartburn, normal endoscopy, normal acid exposure, and PPI failure, regardless of symptom-reflux correlation	Excludes patients with positive symptom-reflux correlation (now classified as reflux hypersensitivity, A3)
Reflux hypersensitivity	Not a separate entity; included within functional heartburn	Separate category (A3) with its own diagnostic criteria
Required workup	Endoscopy and ambulatory pH monitoring recommended	Endoscopy, ambulatory reflux monitoring (with symptom correlation analysis), and high-resolution manometry required
Motor disorder exclusion	Not explicitly required	Explicitly required (HRM to exclude major motor disorders per Chicago Classification)
EoE exclusion	Not explicitly required	Explicitly required (biopsies to exclude EoE)
Frequency threshold	At least once per week (some interpretations)	At least twice per week

The practical consequence of these changes is that the Rome IV definition of functional heartburn identifies a more precisely defined patient population. Patients who would have been labeled as functional heartburn under Rome III may now be reclassified as reflux hypersensitivity, NERD (if more thorough testing reveals abnormal acid exposure), or an esophageal motor disorder. This reclassification improves diagnostic specificity and allows for more targeted treatment.

Overlap with Other Functional Gastrointestinal Disorders

Functional heartburn frequently coexists with other functional gastrointestinal disorders, reflecting the shared pathophysiological mechanisms of visceral hypersensitivity and brain-gut axis dysregulation across the gastrointestinal tract.

• Functional dyspepsia: Up to 40 to 50 percent of patients with functional heartburn also meet criteria for functional dyspepsia (Rome IV B1). The overlap likely reflects shared sensory and motor abnormalities in the upper gastrointestinal tract.
• Irritable bowel syndrome (IBS): IBS is present in approximately 30 to 40 percent of functional heartburn patients, consistent with the concept that visceral hypersensitivity can be a pan-intestinal phenomenon.
• Functional chest pain (A1): Some patients experience both burning (heartburn-type) and non-burning (pressure, tightness) retrosternal symptoms, blurring the boundary between functional heartburn and functional chest pain.
• Globus (A4): The sensation of a lump or foreign body in the throat may coexist with functional heartburn, particularly in patients with esophageal hypervigilance.

When multiple functional gastrointestinal disorders coexist, a holistic management approach that addresses the shared underlying mechanisms (central sensitization, psychological comorbidity, autonomic dysfunction) is more effective than treating each condition in isolation.

Prognosis and Natural History

The natural history of functional heartburn is not as well characterized as that of GERD. Available longitudinal data suggest that functional heartburn tends to follow a chronic, fluctuating course. Some patients experience spontaneous improvement over time, while others have persistent or recurring symptoms that require ongoing management.

Factors associated with a less favorable prognosis include severe baseline symptom intensity, presence of comorbid anxiety or depression, high levels of symptom catastrophizing, and the presence of overlapping functional gastrointestinal disorders. Conversely, patients who engage with psychological therapies and neuromodulator treatment tend to have better long-term outcomes.

There is no evidence that functional heartburn progresses to organic esophageal disease. Specifically, patients with functional heartburn are not at increased risk for erosive esophagitis, Barrett's esophagus, or esophageal malignancy. This reassuring natural history should be communicated to patients as part of the educational component of management.

Special Populations

Elderly Patients

In older patients, the differential diagnosis of retrosternal burning expands to include cardiac ischemia, medication-related esophagitis (particularly from bisphosphonates, NSAIDs, and potassium supplements), and esophageal malignancy. The threshold for endoscopic evaluation should be lower in elderly patients with new-onset heartburn. Additionally, the use of tricyclic antidepressants in this population requires careful consideration of anticholinergic side effects, fall risk, cardiac conduction abnormalities, and potential drug interactions.

Patients with Anxiety Disorders

Patients with prominent anxiety disorders may be particularly prone to esophageal hypervigilance and symptom amplification. In these patients, SSRIs or SNRIs may be preferred over TCAs as first-line neuromodulators because of their dual benefit for both the anxiety disorder and the esophageal symptom. Cognitive behavioral therapy can simultaneously address the anxiety disorder and the functional heartburn, making it an especially efficient intervention in this population.

Post-Fundoplication Patients

Patients who undergo anti-reflux surgery (Nissen or Toupet fundoplication) for presumed refractory GERD may continue to experience heartburn symptoms postoperatively if the underlying diagnosis was actually functional heartburn rather than true reflux disease. This scenario underscores the critical importance of completing the full Rome IV-recommended workup (including ambulatory reflux monitoring and manometry) before considering surgical intervention for PPI-refractory heartburn.

Limitations of the Rome IV Criteria for Functional Heartburn

• Diagnostic burden: The criteria require multiple invasive and costly investigations (endoscopy with biopsies, ambulatory reflux monitoring, high-resolution manometry) in addition to a prolonged PPI trial. This extensive workup may not be readily accessible in all clinical settings, particularly in primary care or resource-limited environments.
• Symptom correlation metrics: The distinction between functional heartburn and reflux hypersensitivity hinges on symptom association probability (SAP) and symptom index (SI), which have known limitations in sensitivity, specificity, and reproducibility. Day-to-day variability in reflux patterns and symptom reporting can lead to different classifications on repeat testing.
• Indeterminate acid exposure: Patients with AET values in the indeterminate range (4 to 6 percent) cannot be confidently classified as GERD or functional heartburn based on AET alone. Adjunctive metrics such as MNBI and PSPW index can help but are not yet universally incorporated into clinical practice.
• Snapshot testing: Ambulatory reflux monitoring provides a 24 to 96-hour snapshot that may not represent the patient's typical reflux pattern. Symptom variability, dietary changes during testing, and the artificial testing environment may all influence results.
• Subjective symptom assessment: Like all Rome criteria, the diagnosis ultimately rests on subjective symptom reporting, which is influenced by patient recall, psychological state, cultural factors, and the clinical context of the evaluation.
• Evolving diagnostic landscape: As novel biomarkers and diagnostic technologies (such as mucosal impedance testing and esophageal mucosal integrity assessment) continue to develop, the boundary between functional heartburn and subtle forms of reflux disease may shift, potentially reclassifying some functional heartburn patients.

Practical Pearls for Clinical Use

• Functional heartburn is a diagnosis of exclusion that requires a complete negative workup. Do not apply this label based on clinical impression alone.
• Always verify PPI adherence and timing before labeling a patient as a PPI non-responder. A surprisingly large proportion of apparent PPI failures are attributable to incorrect dosing or non-adherence.
• Obtain esophageal biopsies during endoscopy even if the mucosa looks normal. EoE can be macroscopically subtle, and missing this diagnosis leads to inappropriate treatment.
• Perform ambulatory reflux monitoring off PPI therapy (at least 7 days off) for the initial diagnostic study. On-PPI testing is primarily reserved for patients who have already demonstrated abnormal acid exposure off PPI and are being evaluated for adequacy of acid suppression.
• Pay close attention to symptom-reflux correlation metrics. The distinction between functional heartburn (negative correlation) and reflux hypersensitivity (positive correlation) directly influences treatment decisions.
• High-resolution manometry should not be skipped. Major motor disorders, especially Type III achalasia, can mimic heartburn and require fundamentally different treatment.
• When initiating neuromodulator therapy, start with a low dose (e.g., amitriptyline 10 mg at bedtime) and titrate slowly. Explain to the patient that the medication targets nerve sensitivity rather than mood, and that therapeutic benefit may take 4 to 8 weeks to become apparent.
• Refer for psychological therapy early in the treatment course rather than as a last resort. CBT and esophageal-directed hypnotherapy have robust evidence and should be considered first-line interventions alongside neuromodulators.
• Avoid repeated endoscopies and diagnostic testing once the workup is complete and the diagnosis is established. Excessive testing can reinforce patient anxiety and hypervigilance.
• Screen for and address overlapping functional gastrointestinal disorders. Treating functional heartburn in isolation when the patient also has functional dyspepsia or IBS is unlikely to produce satisfactory outcomes.